180 related articles for article (PubMed ID: 29497173)
1. Pirfenidone reduces profibrotic responses in human dermal myofibroblasts, in vitro.
Hall CL; Wells AR; Leung KP
Lab Invest; 2018 May; 98(5):640-655. PubMed ID: 29497173
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone attenuates the profibrotic contractile phenotype of differentiated human dermal myofibroblasts.
Wells AR; Leung KP
Biochem Biophys Res Commun; 2020 Jan; 521(3):646-651. PubMed ID: 31679692
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone suppresses MAPK signalling pathway to reverse epithelial-mesenchymal transition and renal fibrosis.
Li Z; Liu X; Wang B; Nie Y; Wen J; Wang Q; Gu C
Nephrology (Carlton); 2017 Aug; 22(8):589-597. PubMed ID: 27245114
[TBL] [Abstract][Full Text] [Related]
4. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy.
Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K
Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pirfenidone on TGF-β1-Induced Myofibroblast Differentiation and Extracellular Matrix Homeostasis of Human Orbital Fibroblasts in Graves' Ophthalmopathy.
Wu SB; Hou TY; Kau HC; Tsai CC
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680057
[TBL] [Abstract][Full Text] [Related]
6. Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts.
Zhou C; Liu F; Gallo PH; Baratz ME; Kathju S; Satish L
BMC Musculoskelet Disord; 2016 Nov; 17(1):469. PubMed ID: 27835939
[TBL] [Abstract][Full Text] [Related]
7. Fluorofenidone inhibits transforming growth factor-beta1-induced cardiac myofibroblast differentiation.
Chen LX; Yang K; Sun M; Chen Q; Wang ZH; Hu GY; Tao LJ
Pharmazie; 2012 May; 67(5):452-6. PubMed ID: 22764581
[TBL] [Abstract][Full Text] [Related]
8. Pirfenidone suppresses TGF‑β1‑induced human intestinal fibroblasts activities by regulating proliferation and apoptosis via the inhibition of the Smad and PI3K/AKT signaling pathway.
Sun Y; Zhang Y; Chi P
Mol Med Rep; 2018 Oct; 18(4):3907-3913. PubMed ID: 30152848
[TBL] [Abstract][Full Text] [Related]
9. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
Conte E; Gili E; Fagone E; Fruciano M; Iemmolo M; Vancheri C
Eur J Pharm Sci; 2014 Jul; 58():13-9. PubMed ID: 24613900
[TBL] [Abstract][Full Text] [Related]
10. FGF2-mediated attenuation of myofibroblast activation is modulated by distinct MAPK signaling pathways in human dermal fibroblasts.
Dolivo DM; Larson SA; Dominko T
J Dermatol Sci; 2017 Dec; 88(3):339-348. PubMed ID: 28899582
[TBL] [Abstract][Full Text] [Related]
11. Human xylosyltransferase-I - a new marker for myofibroblast differentiation in skin fibrosis.
Faust I; Roch C; Kuhn J; Prante C; Knabbe C; Hendig D
Biochem Biophys Res Commun; 2013 Jul; 436(3):449-54. PubMed ID: 23747722
[TBL] [Abstract][Full Text] [Related]
12. XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-β1-stimulated C3H10T1/2 cells via Smad2/4.
Jin SF; Ma HL; Liu ZL; Fu ST; Zhang CP; He Y
Exp Cell Res; 2015 Dec; 339(2):289-99. PubMed ID: 26589264
[TBL] [Abstract][Full Text] [Related]
13. Investigating the effects of Pirfenidone on TGF-β1 stimulated non-SMAD signaling pathways in Dupuytren's disease -derived fibroblasts.
Zhou C; Zeldin Y; Baratz ME; Kathju S; Satish L
BMC Musculoskelet Disord; 2019 Mar; 20(1):135. PubMed ID: 30927912
[TBL] [Abstract][Full Text] [Related]
14. Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells.
Molina-Molina M; Machahua-Huamani C; Vicens-Zygmunt V; Llatjós R; Escobar I; Sala-Llinas E; Luburich-Hernaiz P; Dorca J; Montes-Worboys A
BMC Pulm Med; 2018 Apr; 18(1):63. PubMed ID: 29703175
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways.
Lv Q; Wang J; Xu C; Huang X; Ruan Z; Dai Y
Mol Med; 2020 May; 26(1):49. PubMed ID: 32448163
[TBL] [Abstract][Full Text] [Related]
16. Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro.
Stahnke T; Kowtharapu BS; Stachs O; Schmitz KP; Wurm J; Wree A; Guthoff RF; Hovakimyan M
PLoS One; 2017; 12(2):e0172592. PubMed ID: 28231275
[TBL] [Abstract][Full Text] [Related]
17. Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19.
Choi K; Lee K; Ryu SW; Im M; Kook KH; Choi C
Mol Vis; 2012; 18():1010-20. PubMed ID: 22550395
[TBL] [Abstract][Full Text] [Related]
18. A PPAR-Gamma Agonist Rosiglitazone Suppresses Fibrotic Response in Human Pterygium Fibroblasts by Modulating the p38 MAPK Pathway.
Nuwormegbe SA; Sohn JH; Kim SW
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5217-5226. PubMed ID: 29049722
[TBL] [Abstract][Full Text] [Related]
19. Potential treatment for vocal fold scar with pirfenidone.
Kodama H; Kumai Y; Nishimoto K; Toya Y; Miyamaru S; Furushima S; Yumoto E
Laryngoscope; 2018 May; 128(5):E171-E177. PubMed ID: 29171670
[TBL] [Abstract][Full Text] [Related]
20. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis.
Togami K; Kanehira Y; Tada H
Biol Pharm Bull; 2013; 36(10):1525-7. PubMed ID: 24088250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
